Roger Rooswinkel
Directeur/Bestuurslid bij Pheon Therapeutics Ltd.
Profiel
Roger Rooswinkel is currently a Director at Pheon Therapeutics Ltd.
He previously worked as a Non-Executive Director at Achilles Therapeutics Plc.
Actieve functies van Roger Rooswinkel
| Bedrijven | Functie | Begin |
|---|---|---|
Pheon Therapeutics Ltd.
 Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Roger Rooswinkel
| Bedrijven | Functie | Einde |
|---|---|---|
| ACHILLES THERAPEUTICS PLC | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
